$ALMS

AKKARAJU SRINIVAS purchased $10.7M of ALMS (indirect holdings)

AKKARAJU SRINIVAS purchased 986,721 indirectly-held shares of ALUMIS INC. (ALMS) at an average of $10.87 ($10.63–$11.17, $10.73M total) across 4 trades over 2026-09-04 to 2026-09-08.

Original reporting
SEC EDGAR · AKKARAJU SRINIVAS
Published Sep 10, 2026, 1:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Bullish
high confidence
Mentioned
$ALMS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSBullishMed
01

Why it matters

The insider buy adds a positive data point for Alumis, potentially prompting short-term buying pressure.

02

Market read

A material insider purchase by a director can move the stock and influence investor sentiment.

03

What to watch

No disclosed 10b5-1 plan; the timing may be opportunistic based on price rather than fundamentals.

Relevance 8/10Novelty 8/10Timing: filed 2026-09-09

Background

SEC Form 4 filings disclose insider transactions; director purchases are closely watched for signals.

Company-level read

Ticker impact

$ALMSBullishHigh confidence
Context

Director Akkaraju Srivinas bought 986,721 shares of Alumis Inc. for $10.7M, increasing his stake to 2,298,783 shares.

Expected impact

Potential short-term upside as the market may view the purchase as a bullish signal.

Evidence & confidence

A $10.7M purchase by a director is material and likely to influence investor sentiment.

Market effects

May signal confidence in the specialty chemicals sector, potentially supporting peers.

Limited to US markets where Alumis trades.

Low, as the filing concerns a single mid-cap US company.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Alumis Inc.

    Specialty chemicals manufacturer listed on NYSE under ticker ALMS.

  • Akkaraju Srivinas

    Director of Alumis Inc. who executed the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Why is Alumis stock rallying today?

Alumis (ALMS) stock rose 6.3% in pre-market trading after presenting long-term skin-clearance data for envudeucitinib at the Cantor Fitzgerald Global Healthcare Conference. Management highlighted potential partnerships and insider Srinivas Akkaraju bought 986,000 shares. The FDA application for envudeucitinib is expected in Q4 2026.

$ALMSMedAI 8/10

Alumis (ALMS) Plans to Advance Envudeucitinib After LUMUS Missed in the Overall Population

Alumis Inc. (ALMS) reported that its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet primary or secondary endpoints in the overall population. However, a prespecified subgroup with high interferon gene signature showed numerically higher responses. The company plans to discuss Phase 3 trial design with regulators. Envudeucitinib was generally well tolerated.

$ALMSMedAI 8/10

Alumis Phase 2b LUMUS Trial Misses Endpoints; Stock Plunges

Alumis Inc. (ALMS) reported Phase 2b LUMUS trial results for Envudeucitinib in SLE, missing primary and secondary endpoints overall but showing promise in a subset of patients with high interferon gene signature. The drug demonstrated improvements in several measures in this subgroup and was well tolerated. The company plans to discuss Phase 3 development with regulators. ALMS stock fell over 55% in pre-market trading.